These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 19057210)

  • 1. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
    Wang C
    Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ; Gales MA
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?
    Gravas S; Melekos MD
    Curr Opin Urol; 2009 Jan; 19(1):49-54. PubMed ID: 19057216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower urinary tract symptoms and sexual dysfunction: a common approach.
    Giuliano F
    BJU Int; 2008 Mar; 101 Suppl 3():22-6. PubMed ID: 18307682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common approach to managing lower urinary tract symptoms and erectile dysfunction.
    Taylor JM; Desouza R; Wang R
    Asian J Androl; 2008 Jan; 10(1):45-53. PubMed ID: 18087643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
    Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
    MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
    [No Abstract]   [Full Text] [Related]  

  • 15. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.
    Chung BH; Lee JY; Lee SH; Yoo SJ; Lee SW; Oh CY
    Int J Impot Res; 2009; 21(2):122-8. PubMed ID: 19194451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of benign prostatic hypertrophy.
    Nix JW; Carson CC
    Can J Urol; 2007 Dec; 14 Suppl 1():53-7. PubMed ID: 18163946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE5 inhibitors for LUTS.
    Mouli S; McVary KT
    Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.
    Lee JY; Park SY; Jeong TY; Moon HS; Kim YT; Yoo TK; Choi HY; Park HY; Lee SW
    J Androl; 2012; 33(3):397-403. PubMed ID: 21868753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.